Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

Analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Silence Therapeutics in a report issued on ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

H.C. Wainwright raised the firm’s price target on BlackSky (BKSY) to $20 from $12 and keeps a Buy rating on the shares. The firm says that as ...

H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

Fintel reports that on January 30, 2025, HC Wainwright & Co. initiated coverage of Knightscope (NasdaqCM:KSCP) with a Buy recommendation. As of January 28, 2025, the average one-year price target ...

Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has initiated coverage on the ...